{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:17:26Z","timestamp":1782307046349,"version":"3.54.5"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009139","name":"DZIF","doi-asserted-by":"publisher","award":["FF 01.901"],"award-info":[{"award-number":["FF 01.901"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"DZIF","doi-asserted-by":"publisher","award":["TTU 01.806"],"award-info":[{"award-number":["TTU 01.806"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Lu477\/23\\u20132"],"award-info":[{"award-number":["Lu477\/23\\u20132"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KFO342 P06"],"award-info":[{"award-number":["KFO342 P06"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["B13"],"award-info":[{"award-number":["B13"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1009 B02"],"award-info":[{"award-number":["SFB1009 B02"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.coviro.2023.101304","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T14:20:19Z","timestamp":1677248419000},"page":"101304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["MEK inhibitors as novel host-targeted antivirals with a dual-benefit mode of action against hyperinflammatory respiratory viral diseases"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4490-3052","authenticated-orcid":false,"given":"Stephan","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Pleschka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Planz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2023.101304_bib1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41584-021-00608-z","article-title":"Systemic and organ-specific immune-related manifestations of COVID-19","volume":"17","author":"Ramos-Casals M","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coviro.2023.101304_bib2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.humpath.2008.08.015","article-title":"Systemic infection of avian influenza A virus H5N1 subtype in humans","volume":"40","author":"Zhang","year":"2009","journal-title":"Hum Pathol"},{"key":"10.1016\/j.coviro.2023.101304_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10456-020-09753-7","article-title":"Microvascular dysfunction in COVID-19: the MYSTIC study","volume":"24","author":"Rovas","year":"2021","journal-title":"Angiogenesis"},{"key":"10.1016\/j.coviro.2023.101304_bib4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/irv.12446","article-title":"Influenza antivirals currently in late-phase clinical trial","volume":"11","author":"Koszalka","year":"2017","journal-title":"Influenza Other Respir Virus"},{"key":"10.1016\/j.coviro.2023.101304_bib5","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.coviro.2023.101304_bib6","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral Nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2023.101304_bib7","first-page":"497","article-title":"Repurposed antiviral drugs for COVID-19 \u2014 Interim WHO solidarity trial results","volume":"384","author":"WHO","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2023.101304_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ph15060739","article-title":"Will the use of pharmacogenetics improve treatment efficiency in COVID-19?","volume":"15","author":"Franczyk","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.coviro.2023.101304_sbref9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2023.101304_bib10","doi-asserted-by":"crossref","first-page":"8997","DOI":"10.1074\/jbc.R500020200","article-title":"The M2 proton channels of influenza A and B viruses","volume":"281","author":"Pinto","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2023.101304_bib11","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jama.295.8.joc60020","article-title":"Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States","volume":"295","author":"Bright","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.coviro.2023.101304_bib12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/QCO.0b013e3283199797","article-title":"The potential impact of neuraminidase inhibitor resistant influenza","volume":"21","author":"Lackenby","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.coviro.2023.101304_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2023.101304_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9051094","article-title":"Global genomic analysis of SARS-CoV-2 RNA dependent RNA polymerase evolution and antiviral drug resistance","volume":"9","author":"Mari","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.coviro.2023.101304_bib15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1152\/physrev.1999.79.1.143","article-title":"Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human","volume":"79","author":"Widmann","year":"1999","journal-title":"Physiol Rev"},{"key":"10.1016\/j.coviro.2023.101304_bib16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1128\/MMBR.00031-10","article-title":"Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases","volume":"75","author":"Cargnello","year":"2011","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.coviro.2023.101304_bib17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.coviro.2023.101304_sbref18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/35060098","article-title":"Influenza virus propagation is impaired by inhibition of the Raf\/MEK\/ERK signalling cascade","volume":"3","author":"Pleschka","year":"2001","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.coviro.2023.101304_bib19","doi-asserted-by":"crossref","first-page":"16707","DOI":"10.1074\/jbc.M510233200","article-title":"Membrane accumulation of influenza A virus hemagglutinin triggers nuclear export of the viral genome via protein kinase C\u03b1-mediated activation of ERK signaling","volume":"281","author":"Marjuki","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2023.101304_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2017.00027","article-title":"HA triggers the switch from MEK1 SUMOylation to phosphorylation of the ERK pathway in influenza A virus\u2013infected cells and facilitates its infection","volume":"7","author":"Wang","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.coviro.2023.101304_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0014-5793(04)00108-5","article-title":"MEK inhibition impairs influenza B virus propagation without emergence of resistant variants","volume":"561","author":"Ludwig","year":"2004","journal-title":"FEBS Lett"},{"key":"10.1016\/j.coviro.2023.101304_bib22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S1369-5274(02)00346-6","article-title":"Influenza virus still surprises","volume":"5","author":"Yewdell","year":"2002","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.coviro.2023.101304_sbref23","article-title":"Dissecting the mechanism of signaling-triggered nuclear export of newly synthesized influenza virus ribonucleoprotein complexes","volume":"178","author":"Schreiber","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2023.101304_bib24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1462-5822.2010.01556.x","article-title":"Influenza A virus-induced early activation of ERK and PI3K mediates V-ATPase-dependent intracellular pH change required for fusion","volume":"13","author":"Marjuki","year":"2011","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.coviro.2023.101304_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkp161","article-title":"Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy","volume":"64","author":"Ludwig","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coviro.2023.101304_bib26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.antiviral.2013.04.008","article-title":"Development of cellular signaling pathway inhibitors as new antivirals against influenza","volume":"98","author":"Planz","year":"2009","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2023.101304_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22101551","article-title":"Current development status of MEK inhibitors","volume":"22","author":"Cheng","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.coviro.2023.101304_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116922","article-title":"The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers","volume":"70","author":"Wang","year":"2022","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.coviro.2023.101304_sbref29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2011.05.009","article-title":"Inhibition of influenza virus induced NF-\u03baB and Raf\/MEK\/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo","volume":"92","author":"Pinto","year":"2011","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2023.101304_bib30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.antiviral.2011.08.002","article-title":"Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo","volume":"92","author":"Droebner","year":"2011","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2023.101304_bib31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.antiviral.2017.03.024","article-title":"The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo","volume":"142","author":"Haasbach","year":"2017","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2023.101304_bib32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.antiviral.2018.07.006","article-title":"The clinically approved MEK inhibitor trametinib efficiently blocks influenza A virus propagation and cytokine expression","volume":"157","author":"Schr\u00e4der","year":"2018","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2023.101304_bib33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.antiviral.2013.03.006","article-title":"Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro","volume":"98","author":"Haasbach","year":"2013","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2023.101304_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.611958","article-title":"Improved in vitro efficacy of baloxavir marboxil against influenza A virus infection by combination treatment with the MEK inhibitor ATR-002","volume":"12","author":"Hamza","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.coviro.2023.101304_bib35","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1515\/BC.2008.145","article-title":"RNA viruses and the mitogenic Raf\/MEK\/ERK signal transduction cascade","volume":"389","author":"Pleschka","year":"2008","journal-title":"Biol Chem"},{"key":"10.1016\/j.coviro.2023.101304_bib36","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1128\/JVI.75.10.4871-4877.2001","article-title":"MEK-specific inhibitor U0126 blocks spread of Borna disease virus in culture cells","volume":"75","author":"Planz","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101304_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/cmi.12955","article-title":"Late activation of the Raf\/MEK\/ER pathway is required for translocation of the respiratory syncytial virus F protein to the plasma membrane an efficient viral replication","volume":"21","author":"Preugschas","year":"2019","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.coviro.2023.101304_bib38","doi-asserted-by":"crossref","first-page":"8634","DOI":"10.1128\/JVI.00418-07","article-title":"Dynein-dependent transport of the hantaan virus nucleocapsid protein to the endoplasmic reticulum-Golgi intermediate compartment","volume":"81","author":"Ramanathan","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101304_bib39","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1128\/JVI.01705-06","article-title":"Suppression of coronavirus replication by inhibition of the MEK signaling pathway","volume":"81","author":"Cai","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101304_bib40","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1096\/fj.06-6589com","article-title":"Spike protein of SARS-CoV stimulates cyclooxygenase-2 expression via both calcium-dependent and calcium-independent protein kinase C pathways","volume":"21","author":"Liu","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.coviro.2023.101304_sbref41","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-021-04085-1","article-title":"The MEK1\/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine\/chemokine responses","volume":"79","author":"Schreiber","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.coviro.2023.101304_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091776","article-title":"The MEK1\/2 inhibitor ATR-002 (Zapnometinib) synergistically potentiates the antiviral effect of direct-acting anti-SARS-CoV-2 drugs","volume":"14","author":"Schreiber","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.coviro.2023.101304_sbref43","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nri3495","article-title":"Mitogen-activated protein kinases in innate immunity","volume":"13","author":"Arthur","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coviro.2023.101304_bib44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jaut.2017.06.006","article-title":"Small molecules to the rescue: inhibition of cytokine signaling in immune-mediated diseases","volume":"85","author":"Gadina","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coviro.2023.101304_bib45","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.smim.2010.04.010","article-title":"The TCR-mediated signaling pathways that control the direction of helper T cell differentiation","volume":"22","author":"Nakayama","year":"2010","journal-title":"Semin Immunol"},{"key":"10.1016\/j.coviro.2023.101304_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141903","article-title":"Targeting tuberculosis and HIV infection-specific regulatory T cells with MEK\/ERK signaling pathway inhibitors","volume":"10","author":"Lieske","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2023.101304_bib47","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1023\/B:PHAM.0000041464.27579.d0","article-title":"In vitro and in vivo metabolism of the anti-cancer agent CI-1040, a MEK inhibitor, in rat, monkey, and human","volume":"21","author":"Wabnitz","year":"2004","journal-title":"Pharm Res"},{"key":"10.1016\/j.coviro.2023.101304_bib48","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1200\/JCO.2005.14.415","article-title":"Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies","volume":"23","author":"Lorusso","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coviro.2023.101304_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104806","article-title":"Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model","volume":"178","author":"Laure","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2023.101304_sbref50","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-27445-7","article-title":"Metabolic conversion of CI-1040 turns a cellular MEK-inhibitor into an antibacterial compound","volume":"8","author":"Bruchhagen","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2023.101304_sbref51","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.893635","article-title":"Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans","volume":"13","author":"Koch-Heier","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coviro.2023.101304_bib52","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nm0517-528","article-title":"Host with the most: targeting host cells instead of pathogens to fight infectious disease","volume":"23","author":"Keener","year":"2017","journal-title":"Nat Med"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625723000044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625723000044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:04:35Z","timestamp":1778832275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625723000044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":52,"alternative-id":["S1879625723000044"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2023.101304","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MEK inhibitors as novel host-targeted antivirals with a dual-benefit mode of action against hyperinflammatory respiratory viral diseases","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2023.101304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101304"}}